BioLineRx (BLRX) had the highest return in 2011 by a US stock in the Biotechnology Industry, returning 30,621.5%.
| ASSET | YEAR | % RETURN |
|---|---|---|
BioLineRx (BLRX) | 2011 | 30,621.52% |
PharmaCyte Biotech (PMCB) | 2011 | 203.33% |
Curis (CRIS) | 2011 | 134% |
Pluri (PLUR) | 2011 | 71.72% |
DiaMedica Therapeutics (DMAC) | 2011 | 70.33% |
Regeneron Pharmaceuticals (REGN) | 2011 | 69.56% |
Biogen (BIIB) | 2011 | 62.6% |
Mesoblast (MESO) | 2011 | 48.48% |
Anika Therapeutics (ANIK) | 2011 | 45.4% |
ImmuCell (ICCC) | 2011 | 44.86% |
Lixte Biotechnology (LIXT) | 2011 | 42.86% |
Alkermes (ALKS) | 2011 | 40.91% |
EXACT Sciences (EXAS) | 2011 | 33.99% |
BioRestorative Therapies (BRTX) | 2011 | 33.33% |
Opko Health (OPK) | 2011 | 32.79% |
Ligand Pharmaceuticals (LGND) | 2011 | 32.33% |
Catalyst Pharmaceuticals (CPRX) | 2011 | 30.3% |
Biomarin Pharmaceutical (BMRN) | 2011 | 27.29% |
VistaGen Therapeutics (VTGN) | 2011 | 24.49% |
Cardiff Oncology (CRDF) | 2011 | 22.22% |
Assembly Biosciences (ASMB) | 2011 | 19.52% |
Kamada (KMDA) | 2011 | 19.11% |
Halozyme Therapeutics (HALO) | 2011 | 18.88% |
Alterity Therapeutics (ATHE) | 2011 | 18.55% |
Amgen (AMGN) | 2011 | 17.53% |
